OpenLegislation

Regulation 34 Deferral of consideration of applications for inclusion in a pharmaceutical list on fitness grounds

United Kingdom

F1(A1)

In this regulation, “A” means, where an application for inclusion in a pharmaceutical list is made by a person who is—

(a)

an individual, the individual making the application;

(b)

a partnership, any partner in the partnership making the application; or

(c)

a body corporate—

(i)

except for the purposes of paragraph (1)(b), (c)(ii), (e), (g), (i) and (k), the body corporate making the application, and

(ii)

any director or superintendent of the body corporate making the application.

(1)

An application for inclusion in a pharmaceutical list by a person F2...who is not already included in it may be deferred if F3NHS England is satisfied that—

(a)

there are, in respect of A F4...—

(i)

criminal proceedings in the United Kingdom, or

(ii)

proceedings elsewhere relating to conduct, which, if it had occurred in the United Kingdom, would constitute a criminal offence,

which, if they result in a conviction, or the equivalent of a conviction, would be likely to lead to F5the person’s removal from the pharmaceutical list, if the person were to be included in it;

(b)

in respect of a body corporate of which A is, or has in the preceding 6 months been, or was at the time of the originating events, a director or superintendent, there are—

(i)

criminal proceedings in the United Kingdom, or

(ii)

proceedings elsewhere relating to conduct, which, if it had occurred in the United Kingdom, would constitute a criminal offence,

which, if they resulted in a conviction, or the equivalent of a conviction, would be likely to lead to F6the person’s removal from the pharmaceutical list, if the person were to be included in it;

(c)

there is an investigation anywhere in the world—

(i)

by A's F7... licensing or regulatory body, or

(ii)

relating to A F8... in A's professional capacity (including one by NHS England or another primary care organisation),

which, if the outcome were adverse, would be likely to lead to the removal of F9the person from the pharmaceutical list if the person were to be included in it;

(d)

A F10...is suspended from a relevant list;

(e)

a body corporate of which A F11... was, at the time of the originating events, a director or superintendent, is suspended from a relevant list;

(f)

the First-tier Tribunal is considering an appeal by A F12... against a decision of NHS England or another primary care organisation—

(i)

to refuse an application for inclusion in a relevant list, or

(ii)

to include A conditionally in, or to remove or contingently remove A from, a relevant list,

and if that appeal were to be unsuccessful, NHS England would be likely to remove F13the person from the pharmaceutical list if the person were to be included in it;

(g)

the First-tier Tribunal is considering an appeal by a body corporate of which A F14... was, at the time of the originating events, or has in the preceding 6 months been, a director or superintendent, against a decision of NHS England or another primary care organisation—

(i)

to refuse an application by that body corporate for inclusion in its list,

(ii)

to include A conditionally in, or to remove or contingently remove A from, a relevant list,

and if that appeal were to be unsuccessful NHS England would be likely to remove F15the person from the pharmaceutical list if the person were to be included in it;

(h)

A F16... is being investigated by the F17NHS CFA in relation to any fraud, where the result, if adverse, would be likely to lead to the removal of F18the person from the pharmaceutical list if the person were to be included in it;

(i)

a body corporate, of which A F19...was, at the time of the originating events, a director or superintendent, is being investigated by the F20NHS CFA in relation to any fraud, where the result if adverse would be likely to lead to the removal of F21the person from the pharmaceutical list if the person were to be included in it;

(j)

the First-tier Tribunal is considering an application from NHS England or a Local Health Board for a national disqualification of A F22...;

(k)

the First-tier Tribunal is considering an application from NHS England or a Local Health Board for a national disqualification of a body corporate of which A F23... was, at the time of the originating events, a director or superintendent; or

(l)

NHS England or another primary care organisation, for a reason relating to unsuitability, fraud or efficiency of service provision—

(i)

is considering removal (other than voluntary removal) or contingent removal of the applicant from a relevant list, or

(ii)

has taken a decision to remove (other than voluntary removal) or contingently remove F24the applicant from a relevant list but that decision has yet to take effect.

(2)

NHS England may only defer a decision under paragraph (1) until—

(a)

the outcome of the cause for the deferral is known; or

(b)

the reason for the deferral no longer exists.

Annotations

Textual amendments

F1

Reg. 34(A1) inserted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(a)

F2

Word in reg. 34(1) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(i)

F3

Words in Regulations substituted (6.11.2023) by The Health and Care Act 2022 (Further Consequential Amendments) (No. 2) Regulations 2023 (S.I. 2023/1071), reg. 1(1), Sch. para. 1

F4

Words in reg. 34(1)(a) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ii)(aa)

F5

Words in reg. 34(1)(a) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ii)(bb)

F6

Words in reg. 34(1)(b) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iii)

F7

Words in reg. 34(1)(c)(i) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(aa)

F8

Words in reg. 34(1)(c)(ii) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(bb)

F9

Words in reg. 34(1)(c) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(iv)(cc)

F10

Words in reg. 34(1)(d) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(v)

F11

Words in reg. 34(1)(e) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(vi)

F12

Words in reg. 34(1)(f) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(vii)(aa)

F13

Words in reg. 34(1)(f) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(vii)(bb)

F14

Words in reg. 34(1)(g) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(viii)(aa)

F15

Words in reg. 34(1)(g) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(viii)(bb)

F16

Words in reg. 34(1)(h) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ix)(aa)

F17

Words in reg. 34(1)(h) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 5(a)

F18

Words in reg. 34(1)(h) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(ix)(bb)

F19

Words in reg. 34(1)(i) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(x)(aa)

F20

Words in reg. 34(1)(i) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 5(b)

F21

Words in reg. 34(1)(i) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(x)(bb)

F22

Words in reg. 34(1)(j) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(v)

F23

Words in reg. 34(1)(k) omitted (1.4.2014) by virtue of The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(v)

F24

Words in reg. 34(1)(l)(ii) substituted (1.4.2014) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment and Transitional Provision) Regulations 2014 (S.I. 2014/417), regs. 1, 13(b)(xi)